Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Since its first activities in 2008 and 2009, the Response Assessment in NeuroOncology (RANO) group has given guidance on response assessment, trial design, and trial procedures to improve and standardize the way clinical trials in neurooncological studies are performed. To achieve its objectives, a variety of working groups have been initiated that cover many aspects of clinical trial design and outcome assessment in patients with tumors affecting the Central Nervous System. The RANO working groups are built on expertise without a formal structure, which makes rapid responses to new developments possible. RANO is aiming at evidence-based guidelines and recommendations, but in the absence of evidence will provide consensus-based guidance achieved by inviting recognized international experts. In its 15 years of existence, more than 60 RANO papers have been published mostly in high-ranking journals, and its recommendations have been accepted by regulators and industry as guiding principles. RANO organizes two meetings per year, one in conjunction with the annual American Society for Clinical Oncology (ASCO) meeting, and one during the annual Society for Neuro-Oncology meeting. These meetings are open, as are the working groups of RANO. New initiatives are welcomed.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-05-03
DOI
https://doi.org/10.1093/neuonc/noaf118
Citations
6
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
9.75
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Michelle M. Kim, Annick Desjardins, Susan Chang, Jason Fangusaro et al.
6 citations
Neuro-Oncology
Glioma Diagnosis and Treatment
9.75
article

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Michelle M. Kim, Annick Desjardins, Susan Chang, Jason Fangusaro, Johan A F Koekkoek, Martin J. van den Bent, Arjun Sahgal, Lakshmi Nayak, Patrick Y. Wen, Jason T. Huse, Tito R. Mendoza, Eudocia Q. Lee, Philipp Karschnia, Minesh P. Mehta, Nathalie L. Albert, Spyridon Bakas, Wenya Linda Bi, Norbert Galldiks, Javier Villanueva-Meyer, Ugonma Nnenna Chukwueke, José Pablo Leone, Florien Willemijn Boele, Hideho Okada, David A. Reardon, Timothy F. Cloughesy, Raymond Y. Huang, Joshua Budhu, Edward K. Avila, Émilie Le Rhun, David M. Mirsky, Ashlee R. Loughan, Riccardo Soffietti, Mary Jane Lim-Fat, Michael A. Vogelbaum, Joerg-Christian Tonn
article en
6 citations

Abstract

Since its first activities in 2008 and 2009, the Response Assessment in NeuroOncology (RANO) group has given guidance on response assessment, trial design, and trial procedures to improve and standardize the way clinical trials in neurooncological studies are performed. To achieve its objectives, a variety of working groups have been initiated that cover many aspects of clinical trial design and outcome assessment in patients with tumors affecting the Central Nervous System. The RANO working groups are built on expertise without a formal structure, which makes rapid responses to new developments possible. RANO is aiming at evidence-based guidelines and recommendations, but in the absence of evidence will provide consensus-based guidance achieved by inviting recognized international experts. In its 15 years of existence, more than 60 RANO papers have been published mostly in high-ranking journals, and its recommendations have been accepted by regulators and industry as guiding principles. RANO organizes two meetings per year, one in conjunction with the annual American Society for Clinical Oncology (ASCO) meeting, and one during the annual Society for Neuro-Oncology meeting. These meetings are open, as are the working groups of RANO. New initiatives are welcomed.

Neuro-OncologyVol. 27(9)
Indiana University Health (US), Brigham and Women's Hospital (US), Baptist Hospital of Miami (US), University of Leeds (GB), Sunnybrook Health Science Centre (CA), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Emory University (US), Duke University (US), Forschungszentrum Jülich (DE), German Cancer Research Center (DE), University of California, San Francisco (US), University of Cologne (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Virginia Commonwealth University (US), University of Toronto (CA), Florida International University (US), University of Michigan (US), UCLA Health (US), Leiden University Medical Center (NL), St James's University Hospital (GB), UCLA Medical Center (US), Health Sciences Centre (CA), University of California System (US), LMU Klinikum (DE), Moffitt Cancer Center (US), Patient-Centered Outcomes Research Institute (US), Massachusetts General Hospital (US), Universitätsklinikum Erlangen (DE), Integrated Oncology (United States) (US), Children's Hospital Colorado (US), Baptist Health South Florida (US), University Hospital of Zurich (CH), Center for Neuro-Oncology (US), Indiana Cancer Consortium (US), Parker Institute for Cancer Immunotherapy (US), Aflac (United States) (US), Dana-Farber Cancer Institute (US), German Centre for Cardiovascular Research (DE), National Cancer Institute (US), Children's Healthcare of Atlanta (US), Center for Cancer Research (US), Comprehensive Cancer Center Erlangen (DE), Erasmus MC Cancer Institute (NL), University Hospital Cologne (DE), Pediatric Brain Tumor Foundation (US), Neurological Surgery (US), Dana-Farber Brigham Cancer Center (US), Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Deutsches Konsortium für Translationale Krebsforschung (DE), Indiana University School of Medicine, Mass General Brigham (US), University of Turin (IT), Indiana University – Purdue University Indianapolis (US), Ludwig-Maximilians-Universität München (DE), University of Colorado Denver (US)
Partnerships for the goals
Openalex Percentile: Top 2%
Glioma Diagnosis and Treatment
9.75
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.